New data on sebeltralstat, a potential HAE medicine currently being trialled, to be presented at scientific conferences

Data on sebeltralstat, which is currently undergoing testing amongst HAE patients, will be presented across ten abstracts at the forthcoming 14^th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida. The abstract details, shared with HAEi, are:

C1-inhibitor Deficiency & Angioedema Workshop

• In their own words, patient perspectives on time to feeling in control of an HAE attack (P-18)
• Time to end of progression of hereditary angioedema attacks treated with sebetralstat (P-25)
• Impact of injectable HAE on-demand treatments on health-related quality of life: a patient and caregiver interview study (P-29)
• Effectiveness of sebetralstat for the on-demand treatment of mucosal hereditary angioedema attacks: interim analysis from KONFIDENT-S (O-29)
• Anxiety associated with hereditary angioedema attacks: results from the phase 3 KONFIDENT trial of oral sebetralstat (O-32)
• Survey results from Italy, the US, UK, and France: Anxiety in patients using injectable on-demand treatments for hereditary angioedema attacks (P-32)

EAC

• Effectiveness of sebetralstat for severe or very severe hereditary angioedema attacks in KONFIDENT-S
• On-demand treatment of hereditary angioedema attacks with sebetralstat in older adults: Interim analysis from KONFIDENT-S
• Time to end of progression of hereditary angioedema attacks treated with sebetralstat
• Long-Term prophylaxis compliance and healthcare resource utilization in hereditary angioedema: A claims database analysis

Both meetings will take place from 29 May – 1 June 2025.

(Source: KalVista)